<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03525249</url>
  </required_header>
  <id_info>
    <org_study_id>UCAM-CFE-0002</org_study_id>
    <nct_id>NCT03525249</nct_id>
  </id_info>
  <brief_title>Clinical Trial on the Articular Pain of Diagnosed Patients of Arthrosis</brief_title>
  <acronym>FISMEH</acronym>
  <official_title>Randomized Clinical Trial to Analyze the Efficacy of a Supplement Removed From the Internal Membrane of the Egg Shell on the Articular Pain of Diagnosed Patients of Arthrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Católica San Antonio de Murcia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Católica San Antonio de Murcia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, controlled, double-blind clinical trial of three parallel branches to analyze the
      efficacy of a supplement extracted from the internal membrane of the egg shell on the joint
      pain of patients diagnosed with osteoarthritis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pain from baseline at 8 weeks</measure>
    <time_frame>The pain will be measured by a scale twice, at the beginning and at the end of the study (after an 8 week consumption).</time_frame>
    <description>analog visual scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of life test</measure>
    <time_frame>it will be measured twice, once at baseline or at the end of the study after 8 weeks of use</time_frame>
    <description>The quality of life of the subjects will be measured with the WOMAC test. It is a 24-item test that will measure the degree of pain on a scale of: nothing, little, enough, a lot, and a lot) when performing activities in daily life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>functional test</measure>
    <time_frame>Twice, once at the beginning of the trial in basal conditions and once at the end after 8 weeks of consumption.</time_frame>
    <description>The balance and mobility of the subjects will be measured with the Timed Up and Go Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>Twice, once at the beginning of the trial in basal conditions and once at the end after 8 weeks of consumption.</time_frame>
    <description>the arterial pressure will be measured to the subjects</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Comparator Membraflex 500mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>experimental product one dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator Membraflex 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>experimental product two doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo product</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>nutraceutical</intervention_name>
    <description>Subjects will consume a capsule for eight weeks</description>
    <arm_group_label>Comparator Membraflex 500mg</arm_group_label>
    <arm_group_label>Comparator Membraflex 300mg</arm_group_label>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18 years.

          -  Subjects diagnosed with osteoarthritis with functional grades I-III according to the
             modified criteria of the American College of Rheumatology.

          -  Subjects must have persistent knee pain associated with osteoarthritis with an initial
             score of at least 30 mm in the assessment of pain according to the EVA scale.

          -  The subjects should not present in their treatment narcotic drugs or steroidal
             anti-inflammatory or immunosuppressive drugs.

        Exclusion Criteria:

          -  Serious or terminal illnesses.

          -  Subjects who are currently taking glucosamine, chondroitin sulfate, collagen or
             hyaluronic infiltrates or any supplement indicated for joint health.

          -  Subjects with chronic inflammatory diseases that affect the musculoskeletal system
             (rheumatoid arthritis, gout, pseudo-gout, Paget's disease, chronic pain syndrome,
             etc.).

          -  Subjects with a body mass index above 32.

          -  Subjects with a known allergy to eggs.

          -  Pregnant or lactating women.

          -  Inability to understand informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Francisco Javier López Román</last_name>
    <phone>607182717</phone>
    <phone_ext>523</phone_ext>
    <email>jlroman@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Catholic University of Murcia</name>
      <address>
        <city>Murcia</city>
        <zip>30107</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fco Javier López Román</last_name>
      <phone>968278523</phone>
      <email>jlroman@ucam.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2018</study_first_submitted>
  <study_first_submitted_qc>May 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2018</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Católica San Antonio de Murcia</investigator_affiliation>
    <investigator_full_name>Francisco Javier López Román</investigator_full_name>
    <investigator_title>MD. PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Arthralgia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

